Callan Capital LLC Acquires 137 Shares of Amgen Inc. (NASDAQ:AMGN)

Callan Capital LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,506 shares of the medical research company’s stock after buying an additional 137 shares during the period. Callan Capital LLC’s holdings in Amgen were worth $722,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BIP Wealth LLC boosted its position in shares of Amgen by 2.6% in the 4th quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock worth $360,000 after purchasing an additional 32 shares during the last quarter. Southland Equity Partners LLC grew its position in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after buying an additional 34 shares during the period. Acropolis Investment Management LLC grew its position in shares of Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after buying an additional 34 shares during the period. Opal Wealth Advisors LLC increased its stake in shares of Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after acquiring an additional 34 shares during the last quarter. Finally, Marino Stram & Associates LLC boosted its stake in Amgen by 0.7% during the 4th quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after acquiring an additional 34 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research note on Wednesday, April 3rd. StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. UBS Group lowered their price objective on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Finally, Morgan Stanley cut their price objective on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average target price of $296.95.

Amgen Stock Performance

AMGN traded up $0.60 during trading on Friday, hitting $269.98. The stock had a trading volume of 2,436,947 shares, compared to its average volume of 2,822,655. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market cap of $144.81 billion, a price-to-earnings ratio of 21.62, a P/E/G ratio of 2.54 and a beta of 0.58. The company has a 50 day moving average price of $275.10 and a 200-day moving average price of $281.45. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter in the previous year, the company earned $4.09 EPS. The business’s revenue was up 19.8% on a year-over-year basis. As a group, research analysts predict that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.33%. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.